Petrić Miše Branka, Boraska Jelavić Tihana, Strikic Ante, Hrepić Darijo, Tomić Krešimir, Hamm Wolfgang, Tomić Snježana, Prskalo Tomislav, Vrdoljak Eduard
*Department of Oncology, University Hospital Split, Split, Croatia; †Department of Oncology, University Hospital Mostar, Mostar, Bosnia and Herzegovina; ‡Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany; and §Department of Pathology, University Hospital Split, Split, Croatia.
Int J Gynecol Cancer. 2015 Feb;25(2):315-9. doi: 10.1097/IGC.0000000000000336.
Locally advanced cervical cancer (LACC) is one of the leading health problems of the developing countries. We present long-term outcomes of treatment with a concomitant chemobrachyradiotherapy followed by consolidation chemotherapy regimen.
We treated 118 patients with LACC (International Federation of Gynecology and Obstetrics stages IB2-IVA) with external radiotherapy (50 Gy in 25 fractions) and concomitant chemobrachyradiotherapy (low-dose rate). Chemotherapy was applied during brachyradiotherapy (cisplatin on day 1 in combination with 24-hour infusion of ifosfamide and mesna uroprotection). Four cycles of consolidation chemotherapy were given starting 4 weeks after the second concomitant chemobrachyradiotherapy cycle.
After median follow-up period of 99.3 months, we observed acceptable acute and late toxicity, local control rate of 97.5%, and an overall survival of 74.6% at 96 months.
Chemobrachyradiotherapy regimen followed by consolidation chemotherapy described in this article is a valuable treatment option for LACC.
局部晚期宫颈癌(LACC)是发展中国家主要的健康问题之一。我们报告了同步放化疗联合巩固化疗方案治疗的长期结果。
我们对118例LACC患者(国际妇产科联盟分期为IB2-IVA期)进行了外照射放疗(25次分割,共50 Gy)和同步近距离化疗(低剂量率)。在近距离放疗期间进行化疗(第1天给予顺铂,联合24小时输注异环磷酰胺和美司钠进行尿路保护)。在第二个同步近距离化疗周期后4周开始给予4个周期的巩固化疗。
中位随访99.3个月后,我们观察到可接受的急性和晚期毒性,局部控制率为97.5%,96个月时总生存率为74.6%。
本文所述的同步放化疗联合巩固化疗方案是LACC的一种有价值的治疗选择。